RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome

Ultragenyx Pharmaceutical jumps 5% as the FDA accepts UX111 BLA resubmission, setting up a September 2026 decision for a potential first treatment for MPS IIIA.